DigestRedComo funciona
Red
/
Empresas
Or
No verificado

OrsoBio, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

9 Comunicados de prensa

Ver todos los comunicados de prensa
14/06/2026
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0
05/06/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Ferias y Congresos
Industria
OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0
10/02/2026
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Eventos
Industria
OrsoBio Announces Positive Topline Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and Metabolic Liver Disease
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0
16/01/2026
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Industria
OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0
16/12/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
OrsoBio Announces Positive Topline Phase 1b/2a Clinical Data for its Oral Mitochondrial Protonophore TLC-6740 in Combination with Tirzepatide
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0
04/11/2025
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Eventos
Industria
OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0
20/06/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Eventos
Industria
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association’s 85th Scientific Sessions
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0
15/10/2024
Industria
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
OrsoBio Announces Publication of Preclinical Data on Novel Approach for Regulating Metabolic Dysfunction and Reducing Inflammation and Fibrosis
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0
06/09/2024
Mercado laboral
Industria
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
Medicina - Varios
OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders
Fuente
OrsoBio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0